Type a question in ordinary words. Answers are grounded in retrieved KPSGILL pages and identified sources; questions the library cannot support are declined rather than answered from model memory. No advice is given, and no personal health information is accepted.
534 current articles: 398 policy analyses, 127 patient guides, 6 standing trackers and 3 cross-cutting essays, plus 107 superseded records kept at their original addresses. Ask in your own words.
This week’s records, read at the bodies that issued them. Each carries its instrument, its state and its source — a proposal is not law, an agenda is not a decision, a closed comment period is not a final rule, and an audit finding is not a finding of fraud. Record current through · sources last checked · additions of 24–30 August are pending Dr. Gill review; the standing approval of covers the text reviewed then.
EnactedCalifornia · 28 Aug
AB 1956 signed: boys and young men become a suicide-prevention focus population
The Office of Suicide Prevention may focus on them, and must report implementation strategies by 1 July 2028. A permissive statute, not a clinical duty. Bill state
Final agency decisionUnited States · DEA · 28 Aug
Three DEA registration decisions in one day — and why a state licence decides a federal one
A dentist’s registration revoked for want of Ohio authority, effective 28 September; two matters opened by immediate suspension in December. Administrative decisions, not convictions. Ledger
Safety notificationCalifornia · FDA · patient-facing
A Monterey mammography facility was ordered to warn its patients — and has not
Examinations on or after 22 December 2023 may be affected. The facility holds no active MQSA certificate and may not lawfully perform mammography. Record
Final consent orderUnited States · FTC · 25 Aug
Seven surgery centres divested, and ten years of prior notice
The Commission did not block the $3.9 billion Ascension–AmSurg deal; it priced it, and kept a decade of supervision over expansion in five metros. Record
New · Layer 2
The Reform Agenda: what should change, and the words to change it
Bundibugyo Ebola reaches 60 health zones as Uganda’s outbreak is declared over — and the vaccine caveat is the record
5,794 confirmed cases and 2,786 deaths in DRC through 26 August, across six provinces. WHO and Africa CDC announced the end of Uganda’s outbreak on the 27th after the 42-day countdown; DRC began vaccinating frontline workers with Ervebo in Kisangani on the 27th. Two distinctions carry this record: a PHEIC is not a pandemic, and Ervebo’s protection against Bundibugyo virus has not been established — the campaign runs alongside clinical evaluation, not on proven efficacy.
Walmart’s $50M controlled-substance settlement, DermTech’s bankruptcy-bound FCA resolution, a $50K records-delay CAP — and 23 states sue over Title X
DOJ/DEA settled CSA allegations against Walmart pharmacies (no admission; DEA compliance agreement attached). DermTech’s unreliable-melanoma-test allegations resolve as a $5M unsecured claim in its Chapter 11. OCR’s 55th Right of Access action: two years to produce one patient’s records cost Azul Vision $50,000 and a corrective plan. And in litigation — not enforcement — California joined 22 states suing HHS over Title X funding conditions: a filed complaint, no merits ruling.
Settlements: no liability determined · litigation: complaint filed · Update
Appellate decisionUnited States · Fifth Circuit · 26 Aug
The Medicare drug-negotiation program survives the Fifth Circuit — read from the slip opinion, not a summary
National Infusion Center Association v. Kennedy (No. 25-50661): the panel affirmed summary judgment for the government. Nondelegation fails on an intelligible-principle reading; the §5000D excise tax is not a punitive fine; and no manufacturer, provider or patient holds a protected interest — Medicare participation is voluntary. A panel affirmance, not the final word: rehearing and certiorari remain open, and this is a litigation record, not enforcement.
CMS says $1.6 billion in suspect Medicare lab payments stopped — and the label matters as much as the number
157 laboratory providers revoked, with the $1.6B total spanning payment suspensions, overpayment recoupment and law-enforcement referrals — administrative actions driven by AI claim screening. The agency’s headline says “fraudulent”; its own release body says “potentially improper.” Revocation is not conviction, and 157 revoked providers are not 157 fraud verdicts.
Three approvals, three daysUnited States · FDA · 26–28 Aug
A RAS inhibitor for pancreatic cancer, an oral drug for dermatomyositis, a hepcidin mimetic for polycythemia vera
Rasonque (daraxonrasib), first RAS-targeted therapy in metastatic pancreatic adenocarcinoma — median survival 13.2 vs 6.7 months on chemotherapy. Lisraya (brepocitinib), the first FDA-approved oral treatment for dermatomyositis. Mimrylo (rusfertide), the first PV therapy mimicking hepcidin — 76.9% phlebotomy-free vs 32.9% on placebo. All standard approvals on clinical endpoints; none is an accelerated approval.
Three stages, one weekUnited States · DOJ · HHS OCR · 27–28 Aug
Civil-rights process in cross-section: five schools under review, one agency finding, zero court judgments
HHS OCR opened compliance reviews of five medical schools under Title VI and §1557 — expressly reaching no conclusions. A day earlier, DOJ’s Civil Rights Division announced a finding that GW’s medical school intentionally discriminated in admissions — an agency finding headed to settlement negotiation, which GW disputes, and which no court has adjudicated. Review, finding, judgment: three different legal states, and this week shows the first two.
Reviews opened · agency finding · no merits judgment · Update
FCA settlementUnited States · DOJ · 27 Aug
$541.5 million for Medicare Advantage codes the records didn’t support — disclosed by the provider itself
The Villages Health System settled self-disclosed allegations that 2020–2024 diagnosis codes lacked record support or rode on improper chart amendments, inflating risk-adjusted payments. DOJ credited the self-disclosure and cooperation; the resolved claims remain allegations with no determination of liability. The self-report is as instructive as the number.
FCA settlement · no liability determination · Update
Early AlertUnited States · FDA · CDRH · Neonatal
Neonatal CPAP sets with loose cannula connections: do not use affected lots, FDA’s alert says
Specific lots of CooperSurgical’s INCA neonatal nasal CPAP complete and replacement sets may lose the connection between tubing and cannula — loss of CPAP pressure and decreased oxygenation until restored. The instruction is removal: cease use and return; swap tubing or device if it loosens mid-use. No serious injuries or deaths reported as of the 11 August customer letter; not a final recall classification.
The Board adjourns — and the official outcome record is now the wait
The August meeting — panels on the 19th, the quarterly Board 20–21 August — has concluded. On the record read 24 August, no action summary or approved minutes had been located: every agenda item, from the eighteen legislative positions to each panel’s disciplinary matters, holds one state — disposition not yet identified in the publicly available record. Outcomes populate from the official record, never the room.
Public meeting concluded · outcomes pending · Record · Tracker
Effective 21 AugCalifornia · DHCS · Medi-Cal Rx
The Medi-Cal Rx early-refill change is now the rule at the counter
Effective 21 August, refill-too-soon processing for members 21 and older runs under the revised thresholds. A refused refill this week is the new rule working as written, not a coverage loss: no drug left the benefit and no member lost eligibility.
Benefit policy change · final · effective · Record · Ledger
Early AlertsUnited States · FDA · CDRH
Three device Early Alerts: recalled saline in epidural kits, software that drops monitored patients, neonatal circuits pulled
Epidural and convenience kits may contain recalled Huons saline — with spine-proximity risks stated up to meningitis and paralysis; GE HealthCare’s Portrait monitoring software can remove patients and reset alarms during updates; Medline’s neonatal heated-wire breathing circuits are being removed for connector thermal damage. Each alert reports no serious injuries or deaths as of its source date — and none is a final recall classification.
Free rescue inhalers for 10,000 schools, on one statewide standing order
Two albuterol inhalers and 25 spacers per year, free for three years, to every public and charter TK–12 school — shipped under CDPH’s standing order rather than individual prescriptions, with training through the school-nurse workforce. Announced 20 August; private schools buy at $9.50 an inhaler.
Two years for a $110 million telemedicine scheme built on signatures without examinations
The former owner of two telemedicine companies was sentenced in Boston for a Medicare DME scheme: prepopulated orders signed by recruited clinicians, typically without any patient contact, then sold on to suppliers. Adjudicated by guilty plea — and a case study in what converts telehealth staffing offers into billable fraud.
A first therapy for glycogen storage disease type Ia — with the confirmation still owed
FDA granted accelerated approval to Genglycos, a one-time gene therapy and the first approved treatment for GSDIa, indicated to reduce daily cornstarch intake in patients 8 and older. The endpoint is the burden of management, not a hard outcome — and confirmatory trials remain required.
A second treatment for fibrodysplasia ossificans progressiva — and the first addressing flare-ups
FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification and clinician-assessed flare-ups in adults with FOP — the ultra-rare disorder in which connective tissue turns to bone. Trial: 2 and 1 new lesions on the two doses versus 19 on placebo over 56 weeks. Fetal-harm warning; contraception through 6 months after the last dose. Per FDA, the second drug approved for the disease.
FDA opens a public docket on regulating generative-AI medical devices
A discussion paper issued asks how generative-AI devices should be assessed for risk, evaluated before market and monitored after it — including a premarket model built on competency assessment. It is not a rule and not guidance: FDA states it proposes no policy. Feedback to docket FDA-2026-N-7874 closes 19 October.
Discussion paper · FDA Center for Devices and Radiological Health
Closes 30 AugustEuropean Union · EMA
Europe reopens a guideline because quitting-smoking medicines were never studied in vaping
EMA’s concept paper records that its smoking-cessation guideline is neither intended for nor fully applicable to dependence on nicotine delivered without combustion — and is being applied to it anyway. The proposal extends it to all forms of nicotine dependence. A concept paper is not a guideline.
Medicare drug-price negotiation: the comment period closed on 17 August
The comment period on the proposed rule for the Medicare Drug Price Negotiation Program and the Part D benefit closed . Two state axes move separately: the window is closed and the rule is still a proposal. Nothing became final on that date.
Proposed rule · Centers for Medicare & Medicaid Services
Executive orderUnited States · The White House
An order states childhood vaccine recommendations — and directs a plan to split the MMR
Executive Order 14420 recognises recommendations covering 11 diseases on the White House’s own comparison, moves the rest to shared clinical decision-making, and directs HHS to plan for single-disease core vaccines starting with MMR — once such products are domestically available. It amends no schedule, licenses no product, creates no enforceable right and changes no school-entry rule.
EO 14420 · 91 FR 53173 · plans due 8 November · Record
ConsultationAustralia · TGA
TGA consults on making more of the device record public
A consultation running 13 August to 2 October 2026 on expanding what the TGA may lawfully release about medical devices under section 61 of the Therapeutic Goods Act 1989. A consultation is not a decision.
Consultation · Therapeutic Goods Administration
Effective 1 Jan 2027California · DHCS
A whole population leaves managed care — and the deadline lands on the practice
Medi-Cal members with unsatisfactory immigration status move to fee-for-service on 1 January 2027. Eligibility does not change; payment does. A provider not approved through PAVE by that date is unpaid for a patient who is still covered, members are no longer assigned a primary care provider, and Enhanced Care Management and Community Supports do not exist in fee-for-service.
Delivery-system change · enrollment deadline attached · Record
Proposed pathwayUnited States · CMS & FDA
Medicare proposes same-day coverage review for breakthrough devices
The RAPID pathway would issue a proposed national coverage determination the same day FDA authorises an eligible Breakthrough Device, with final coverage targeted 60–90 days after authorisation instead of the year or more the gap has run. Coverage evidence expectations would be negotiated during trial design — which is where the real change sits. Comments close 13 October.
Procedural notice CMS-3487-NC · proposed, not operative · Federal Register
Accelerated approvalUnited States · FDA
FDA grants accelerated approval to Tudriqev in refractory advanced melanoma
On 6 August 2026 the FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), an HSV-1 oncolytic viral therapy, with nivolumab, for anti-PD-1 refractory disease. Accelerated approval rests on a surrogate endpoint and carries a confirmatory-trial obligation.
Marketing authorisation · Food and Drug Administration
Audit findingUnited States · HHS OIG
OIG projects $15.2 million in improper payments for sacroiliac-joint injections
OIG reviewed sessions billed to Medicare between 1 October 2023 and 30 September 2024. Of a 100-session sample, 72 did not comply with Medicare requirements. An audit finding is not a fraud finding and not a rule change.
Audit report · HHS Office of Inspector General
Pathway17The physician-investigation process, stage by stage.Interactive walkthrough — in the workspace
Every page names its reviewing physician and its review date. Where claim-level authority has been mapped, the evidence can be inspected directly, down to the instrument each proposition rests on. Nothing is deleted. Superseded analyses remain at their own addresses, marked as superseded and pointing to the current record, with its original text retained. Editorial standards & ledger